New Research Links Weight-Loss Drugs to Slower Cancer Spread
Recent studies have revealed that popular weight-loss medications known as GLP-1 drugs might actually help slow down the spread of certain cancers. This information is set to be shared at the upcoming 2026 ASCO Annual Meeting in Chicago.
The research, led by the Cleveland Clinic, demonstrated that these drugs could potentially reduce the progression of several cancers related to obesity, including lung, breast, colorectal, and liver cancers.
Key Findings
In this retrospective study, researchers analyzed data from 12,112 patients diagnosed with various stages of obesity-related cancers. About half of the participants began taking GLP-1 medications—such as semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, or pramlintide—after their cancer diagnosis. The other half were administered a different class of diabetes medications, known as DPP-4 inhibitors or “gliptins.”
The results showed that patients using GLP-1 medications experienced a significantly slower progression to stage 4 cancer across four types:
- Non-small cell lung cancer
- Breast cancer
- Colorectal cancer
- Liver cancer
In particular, participants taking GLP-1 drugs had a 50% lower risk for non-small cell lung cancer, a 43% lower risk for breast cancer, a 31% lower risk for colorectal cancer, and a 38% lower risk for liver cancer compared to those using gliptins.
Potential for Further Research
Dr. Mark David Orland, the study’s lead author from the Taussig Cancer Institute, mentioned that these findings indicate a meaningful reduction in cancer progression for those taking GLP-1 medications. He expressed that this could pave the way for more extensive studies in the future.
While some other cancer types, including prostate, pancreatic, and kidney cancers, also showed reduced progression rates with GLP-1 use, these results were not found to be statistically significant.
The study also noted that patients with tumors exhibiting higher levels of GLP-1 receptors had better survival outcomes, with a roughly one-third decrease in mortality risk during the study period.
Looking Ahead
Although the side effects reported by both GLP-1 users and gliptin users were similar, researchers emphasized that more studies are necessary to fully understand how GLP-1 drugs may influence cancer growth and spread.
The current study has limitations, notably that it was observational rather than a randomized clinical trial, which means it couldn’t definitively conclude that GLP-1 drugs directly prevent cancer progression.
Further clinical trials are needed to explore these promising early findings and to clarify the specific mechanisms by which GLP-1s may influence cancer outcomes.
